Clinical Trials Finder
Independent ClinicalTrials.gov directory
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 22, 2026, 5:20 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–20 of 20 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Administration and Dosage of Ketamine Clear all
Completed Not applicable Interventional Results available
View directory record Official record
Conditions
Treatment Resistant Depression, Major Depressive Disorder, Severe Depression
Interventions
Ketamine, Midazolam
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 28, 2019 · Synced May 22, 2026, 5:20 AM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Pain
Interventions
Ketamine 0.15mg/kg, Ketamine 0.3mg/kg, Placebo
Drug · Other
Lead sponsor
Rhode Island Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Sep 6, 2022 · Synced May 22, 2026, 5:20 AM EDT
Completed Phase 2Phase 3 Interventional Results available
View directory record Official record
Conditions
Pain, Postoperative Depression
Interventions
Ketamine, Placebo Comparator
Drug · Other
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 65 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 15, 2020 · Synced May 22, 2026, 5:20 AM EDT
Withdrawn Phase 2 Interventional
View directory record Official record
Conditions
Pain, Acute
Interventions
Ketamine, Morphine
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 64 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 26, 2022 · Synced May 22, 2026, 5:20 AM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Treatment-resistant Depression
Interventions
Esketamine, Placebo, Duloxetine (Oral Antidepressant), Escitalopram (Oral antidepressant), Sertraline (Oral Antidepressant), Venlafaxine Extended Release (XR) (Oral Antidepressant)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 64 Years
Enrollment
346 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
37
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Garden Grove, California + 34 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2025 · Synced May 22, 2026, 5:20 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available
View directory record Official record
Conditions
Acute Pain, Fractures
Interventions
ketamine, morphine
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 21, 2019 · Synced May 22, 2026, 5:20 AM EDT
Completed Phase 2Phase 3 Interventional Results available
View directory record Official record
Conditions
Posttraumatic Stress Disorder (PTSD)
Interventions
Ketamine, Midazolam
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 10, 2021 · Synced May 22, 2026, 5:20 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers
View directory record Official record
Conditions
Administration and Dosage of Ketamine, Endoscopic Sedation
Interventions
Ketamine, Midazolam injection, Fentanyl
Drug
Lead sponsor
Brooke Army Medical Center
Federal
Eligibility
18 Years to 65 Years
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Fort Sam Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 7, 2020 · Synced May 22, 2026, 5:20 AM EDT
Completed Phase 4 Interventional Results available
View directory record Official record
Conditions
Postoperative Pain
Interventions
Ketamine, Placebo
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 80 Years · Female only
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 15, 2023 · Synced May 22, 2026, 5:20 AM EDT
Not listed Phase 3 Interventional Accepts healthy volunteers
View directory record Official record
Conditions
Chronic Pain
Interventions
Ketamine
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Lacey, Washington
Source: ClinicalTrials.gov public record
Updated May 26, 2015 · Synced May 22, 2026, 5:20 AM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Treatment-resistant Depression
Interventions
Esketamine, Placebo, Duloxetine (Oral Antidepressant), Escitalopram (Oral antidepressant), Sertraline (Oral Antidepressant), Venlafaxine Extended Release (XR) (Oral Antidepressant)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 64 Years
Enrollment
236 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
10
States / cities
Birmingham, Alabama • Orange, California • San Rafael, California + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2025 · Synced May 22, 2026, 5:20 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available
View directory record Official record
Conditions
Ketamine-Induced Brain Activity Changes, Psychotic-like Symptoms
Interventions
Ketamine, TAK-063, TAK-063 Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced May 22, 2026, 5:20 AM EDT
Terminated Phase 4 Interventional Results available
View directory record Official record
Conditions
Pain
Interventions
Ketamine, Fentanyl
Drug
Lead sponsor
Antonios Likourezos
Other
Eligibility
3 Years to 17 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated May 7, 2018 · Synced May 22, 2026, 5:20 AM EDT
Recruiting Phase 2 Interventional
View directory record Official record
Conditions
Sickle Cell Disease, Vaso-Occlusive Pain Episode in Sickle Cell Disease, Ketamine Infusion, Pain Management, Vaso-Occlusive Crises
Interventions
Sub-dissociative Ketamine Infusion, Normal Saline Placebo Infusion
Drug
Lead sponsor
Mohsen Saidinejad
Other
Eligibility
5 Years to 20 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Torrance, California
Source: ClinicalTrials.gov public record
Updated Mar 8, 2026 · Synced May 22, 2026, 5:20 AM EDT
Not listed Phase 1 Interventional
View directory record Official record
Conditions
Levodopa-Induced Dyskinesia, Parkinson's Disease
Interventions
Intervention: Ketamine
Drug
Lead sponsor
University of Arizona
Other
Eligibility
30 Years to 85 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 31, 2023 · Synced May 22, 2026, 5:20 AM EDT
Completed Not applicable Interventional Results available
View directory record Official record
Conditions
Pain
Interventions
Ketamine
Procedure
Lead sponsor
Antonios Likourezos
Other
Eligibility
18 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Nov 21, 2017 · Synced May 22, 2026, 5:20 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available
View directory record Official record
Conditions
Chronic Pain
Interventions
Ketamine, Placebo
Drug
Lead sponsor
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Other
Eligibility
18 Years and older
Enrollment
106 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Torrance, California
Source: ClinicalTrials.gov public record
Updated Apr 14, 2021 · Synced May 22, 2026, 5:20 AM EDT
Terminated Phase 1 Interventional Results available
View directory record Official record
Conditions
Endometriosis, Post Operative Pain
Interventions
Ketamine, Placebo
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 65 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 27, 2025 · Synced May 22, 2026, 5:20 AM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Depressive Disorder, Treatment-Resistant
Interventions
Esketamine 56 mg, Esketamine 84 mg, Placebo, Duloxetine (Oral Antidepressant), Escitalopram (Oral Antidepressant), Sertraline (Oral Antidepressant), Venlafaxine Extended Release (XR) (Oral Antidepressant)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 64 Years
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
6
States / cities
Atlanta, Georgia • Shreveport, Louisiana • Gaithersburg, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2025 · Synced May 22, 2026, 5:20 AM EDT
Terminated Phase 2 Interventional Results available
View directory record Official record
Conditions
Treatment Resistant Depression, Major Depressive Disorder, Bipolar Disorder
Interventions
Ketamine
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 23, 2020 · Synced May 22, 2026, 5:20 AM EDT